Assuntos
Eplerenona , Insuficiência Cardíaca , Antagonistas de Receptores de Mineralocorticoides , Humanos , Eplerenona/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Antagonistas de Receptores de Mineralocorticoides/uso terapêutico , Antagonistas de Receptores de Mineralocorticoides/efeitos adversos , Espironolactona/uso terapêutico , Espironolactona/efeitos adversos , Espironolactona/análogos & derivados , Resultado do TratamentoRESUMO
Photocatalytic technology is attracting considerable attention for the advantages of low cost and environmentally friendly properties. In this study, a novel photocatalyst PW9@ZnO/Ag (PZA) was synthesized hydrothermally and characterized by a variety of means. The results indicated that ZnO and Ag NPs were successfully decorated and uniformly dispersed on PW9 to form the composites. The prepared PZA was applied in the degradation of simulated butyl xanthate (BX) beneficiation wastewater both under the UV light and the xenon lamp, and a maximum degradation of 99.83% was obtained under the visible light with 10% ZnO loading, 1 g/L PZA, initial BX concentration of 20 mg/L, and pH 5.5. The PZA was recovered and reused for 5 times, and the degradation rates remained above 70%. Superoxide radical (·O2-) was the main active species for the photocatalytic degradation of BX. The experimental results demonstrate that PZA is a promising photocatalyst, making it a prospective strategy to overcome current challengers in the use of xanthate degradation and beneficiation wastewater treatment under visible light.